Glemanserin Explained

Glemanserin (INN) (developmental code name MDL-11,939) is a drug which acts as a potent and selective 5-HT_2A receptor antagonist.^[1] The first truly selective 5-HT_2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT_2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue.^[2] Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder.^[3] However, it was ultimately found to be ineffective and was not marketed.

See also

• Volinanserin
• Pruvanserin
• Roluperidone
• Lenperone
• Lidanserin

Notes and References

1. Dudley MW, Wiech NL, Miller FP, Carr AA, Cheng HC, Roebel LE, Doherty NS, Yamamura HI, Ursillo RC, Palfreyman MG . 6 . Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT2 receptors . Drug Development Research . 13 . 1 . 29–43 . 1988 . 10.1002/ddr.430130104 . 85075328 .
2. Book: van Wijngaarden I, Soudijn W . 5-HT_2A, 5-HT_2B, and 5-HT_2C Receptor Ligands . Olivier B . Serotonin Receptors and Their Ligands . https://books.google.com/books?id=lfo0hGqIex0C&pg=PA167 . 6 May 2012 . 10 July 1997 . Elsevier . 978-0-444-82041-9 . 167.
3. Sramek JJ, Robinson RE, Suri A, Cutler NR . Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder . Journal of Clinical Psychopharmacology . 15 . 1 . 20–22 . February 1995 . 7714223 . 10.1097/00004714-199502000-00004 .